Toggle Main Menu Toggle Search

Open Access padlockePrints

The Newcastle University research output collection, currently available on ePrints, will shortly be moving to a new open repository platform, Figshare. To prepare for the data migration we have paused adding new content to ePrints, and will resume once the new repository is launched. During this time you will continue to have access to ePrints (but no new content will appear). We will share updates here when available.

Doxorubicin and cisplatin with granulocyte colony-stimulating factor as adjuvant chemotherapy for osteosarcoma: phase II trail of the European Osteosarcoma Intergroup

Lookup NU author(s): Dr Ruth Bridgewater, Emeritus Professor Alan Craft

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Purpose: This report describes the toxicity and feasibility of administering doxorubicin (DOX) and cisplatin (CDDP) at 2-week intervals with granulocyte colony-stimulating factor (G-CSF) to patients with asteosarcoma and the compatibility of this regimen with endoprosthetic surgery performed after three cycles. Patients and Methods: Twenty-four patients with biopsy-proven-osteosarcoma were treated with three preoperative cycles of DOX 25 mg/m(2)/d on days 1 to 3 and CDDP 100 mg/m(2) on day 1 with G-CSF 5 mu g/kg/d on days 4 to 14. Surgery was scheduled at week 6 to be followed by three further cycles of chemotherapy at 2-week intervals. Results: Two-week chemotherapy was feasible, but delays and dose reductions only allowed 74% and 78% of the intended dose-intensity of DOX and CDDP to be administered. Thrombocytopenia accounted for 50% of delays. Significant toxicity included neutropenic sepsis, severe mucositis, prolonged nausea and vomiting, and electrolyte disturbances. Twenty-one limb salvage procedures and one amputation were performed. there were eight episodes of excessive perioperative bleeding. Conclusion: Intensive 2-week chemotherapy with intercurrent surgery is feasible and allows a greater dose-intensity of chemotherapy to be administered compared with the same regimen administered at 3-week intervals without G-CSF. The toxicity is considerable, but manageable. (C) 1994 by American Society of Clinical Oncology.

Publication metadata

Author(s): Ornadel, D., Souhami, R. L., Whelan, J., Nooy, M., Deelvira, C. R., Pringle, J., Lewis, I., Steward, W. P., George, R., Bridgewater, J., Wierzbicki, R., Craft, A. W.

Publication type: Article

Publication status: Published

Journal: Journal of Clinical Oncology

Year: 1994

Volume: 12

Issue: 9

Pages: 1842-1848

Print publication date: 01/09/1994

ISSN (print): 0732-183X

ISSN (electronic): 1527-7755

PubMed id: 7521906

Share